The Democratic Republic of the Congo’s rapidly expanding Ebola outbreak has surpassed 1,700 deaths amid severe community transmission, security challenges, and severe funding gaps. While Health Canada has cleared an early-stage clinical trial for Moderna’s mRNA vaccine candidate, health officials continue to battle widespread mistrust and active-conflict disruptions across Ituri province.
The epidemic sweeping eastern Congo has reached grim milestones as the World Health Organization scales up experimental trials to confront the unprecedented surge. Caused by the rare Bundibugyo strain, the outbreak has recorded 3,802 cases and 1,707 deaths since officials declared it on May 15. The epidemic now ranks as the second-largest Ebola outbreak on record and the fastest-growing.
Ituri Province Epicenter and Community Transmission Risks
The crisis remains heavily concentrated in eastern Congo’s remote Ituri province, which accounts for nearly 90 percent of all reported infections. During his second visit to the regional hub of Bunia, Africa Centres for Disease Control and Prevention Director-General Jean Kaseya noted that officials cannot yet predict when the epidemic will peak.
Compounding the danger, Kaseya cautioned that nearly 80% of new cases stem from community spread rather than active contact tracing. Health teams are currently monitoring more than 17,000 potential contacts, managing to follow up with about 80 percent of them daily. However, responders face a profound epidemiological blind spot: patient zero has not yet been identified.
Health Canada Authorizes Moderna Trial for Bundibugyo Strain
International pharmaceutical efforts are moving at an accelerated pace to counter the virus. Health Canada has given Moderna the green light to launch a clinical trial for an experimental mRNA vaccine targeting the Bundibugyo variant, making Canada the second country to launch a Phase 1 clinical trial for a Bundibugyo vaccine candidate, after the U.K.
The trial, designated as mRNA-1469 and utilizing the same mRNA technology behind Moderna’s COVID-19 vaccine, will enroll approximately 80 healthy adult volunteers across three Canadian sites to evaluate safety and immune response. The initiative is backed by the Coalition for Epidemic Preparedness Innovations, which has pledged up to $50 million to support early testing and manufacturing.
“Following this, Moderna would be required to conduct additional clinical trial phases before it could seek approval from Health Canada for the vaccine. Any final submission would need to meet Health Canada’s stringent safety, efficacy and quality standards before the vaccine could be allowed on the Canadian market.”
Health Canada, Federal Statement
Because the Bundibugyo variant previously lacked any approved vaccines or specific treatments, researchers are relying on unprecedented acceleration in early-stage testing. Vasee Moorthy, acting head of the WHO’s R&D Blueprint programme, noted the speed of the current response.
“If you compare this outbreak to previous Ebola outbreaks, we have been able to start trials more quickly. It’s true that the preclinical data that we’re seeing is promising.”
Vasee Moorthy, acting head of the WHO’s R&D Blueprint programme
Front-Line Obstacles: Insecurity, Aid Shortages, and Worker Strikes
While clinical trials advance in foreign laboratories, health workers on the ground face immense peril and operational gridlock. The WHO reports that more than 100 healthcare workers have been infected since the epidemic began. Response efforts are continually disrupted by armed group violence, attacks on medical facilities, and severe aid funding cuts.
Community mistrust remains a central barrier to containment. Thousands of potential contacts remain untraced due to regional displacement driven by conflict and illegal mining.
The strain has also triggered labor unrest among medical staff facing dangerous conditions and severe wage arrears. Healthcare workers in the hard-hit town of Mongbwalu issued an ultimatum, warning that if nothing is done within 24 hours, we will escalate our action.
Staff in Bunia have previously staged strikes over similar grievances.
Leadership Visits and Treatment Research
High-level international oversight is intensifying as WHO Director-General Tedros Adhanom Ghebreyesus arrives in Kinshasa before traveling to Bunia. Alongside ongoing vaccine trials in the U.K. and Canada, two clinical trials for post-exposure prophylaxis drugs have started enrolling patients in Ituri province.
With neighboring Uganda having successfully declared itself Ebola-free in mid-June following the discharge of its final patient, Congolese health authorities face mounting pressure to stabilize the response. Whether accelerated treatment trials and vaccine testing can outpace the aggressive community spread across eastern Congo remains the defining question for public health officials this week.
